Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.

We are pursuing programs across the spectrum of genomic medicine, with gene and cell therapies in the clinic today and preclinical programs in genome engineering and off-the-shelf cell therapy. Behind these are research efforts thoughtfully focused on leveraging our differentiated zinc finger technology. We are advancing a robust pipeline of wholly owned and partnered programs in rare disease, neurology, oncology and autoimmune indications with the goal of developing genomic medicines that transform the lives of patients.

Our Pipeline

Phase 3

Hemophilia A

Giroctocogene Fitelparvovec

|

Gene therapy
Cell therapy
Genome engineering

Phase 1/2

Fabry Disease

Isaralgagene civaparvovec
Renal Transplant

(Autologous)
TX200
Sickle Cell Disease

SAR445136

Preclinical

Inflammatory Bowel Disease
Renal Transplant

(Allogeneic)
Multiple Sclerosis
Prion
Neurology

Undisclosed
Oncology

KITE-037

|
Oncology

Undisclosed

|
Neuro- developmental Disorders

|
ALS/FTD

|
Huntington’s Disease

|
a-Synuclein

ST-502

|
Tauopathies

ST-501

|
Neurology

DMI

|
Neurology

Undisclosed

|

Collaborations

We seek collaborations that can extend or complement our leading genomic medicine capabilities

Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.

Our Partners

Biogen and Sangamo have a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.

Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.

Mogrify and Sangamo have a collaboration and exclusive license agreement providing Sangamo with access to Mogrify’s cell conversion reprogramming technology, which Sangamo expects will accelerate its development of scalable and accessible CAR-Treg cell therapies.

Novartis and Sangamo have a global licensing collaboration agreement to develop and commercialize gene regulation therapies to address neurodevelopmental targets, including genes linked to autism spectrum disorder and other neurodevelopmental disorders.

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.

Interested in collaborating with us?

Contact Mark McClung, Executive Vice President, Chief Operating Officer

Contact Mark

Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures

Our Pipeline

Collaborations

We seek collaborations that can extend or complement our leading genomic medicine capabilities

Our Partners